



Published in final edited form as:

J Am Chem Soc. 2016 April 27; 138(16): 5202–5205. doi:10.1021/jacs.6b01458.

Symmetry in Cascade Chirality-Transfer Processes: A Catalytic Atroposelective Direct Arylation Approach to BINOL Derivatives

Jin-Zheng Wang[†], Jin Zhou[†], Chang Xu[†], Hongbin Sun^{†,*}, László Kürti^{‡,*}, and Qing-Long Xu^{†,*}

[†]Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease and State Key Laboratory of Natural Medicines, China Pharmaceutical University, 24 Tongjia Xiang, Nanjing 210009, P.R. China

[‡]Department of Chemistry, Rice University, BioScience Research Collaborative, 6500 Main Street, Room 380, Houston, Texas 77030, United States

Abstract

Herein we disclose a scalable organo-catalytic direct arylation approach for the regio- and atroposelective synthesis of non- C_2 -symmetric 2,2'-dihydroxy-1,1'-binaphthalenes (BINOLs). In the presence of catalytic amounts of axially chiral phosphoric acids, phenols and naphthols are coupled with iminoquinones via a cascade process that involves sequential aminal formation, sigmatropic rearrangement, and rearomatization to afford enantiomerically enriched BINOL derivatives in good to excellent yields. Our studies suggest that the (local) symmetry of the initially formed aminal intermediate has a dramatic impact on the level of enantioinduction in the final product. Aminals with a plane of symmetry give rise to BINOL derivatives with significantly lower enantiomeric excess than unsymmetrical ones featuring a stereogenic center. Presumably asymmetric induction in the sigmatropic rearrangement step is significantly more challenging than during aminal formation. Sigmatropic rearrangement of the enantiomerically enriched aminal and subsequent rearomatization transfers the central chirality into axial chirality with high fidelity.

Biaryl compounds that exhibit axial chirality (i.e., hindered rotation about the C–C bond) are common among natural products, pharmaceuticals, ligands, and catalysts (Figure 1A). The ease of racemization in enantiopure biaryls depends on the magnitude of the rotational barrier, which is determined by both the size and number of substituents at the ortho positions flanking the aryl–aryl bond.¹ During the past two decades, both C_2 - and non- C_2 -symmetric axially chiral biaryl compounds^{1a–c} (e.g., BINAP, BINOL, BINAM, NOBIN, and their derivatives; Figure 1A) have played key roles as ligands for transition metals in the development of catalytic enantioselective transformations.² In addition to their role as

*Corresponding Authors: hbsun2000@yahoo.com, qlxu@cpu.edu.cn, kurti.laszlo@rice.edu.

The authors declare no competing financial interest.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.6b01458.

Procedures and characterization data (PDF)

Crystallographic data for **9ea'** (CIF)

“privileged chiral catalysts”,^{2j} recently it was recognized that controlling the chirality of functionalized biaryl structures will have enormous implications in the future development of pharmaceuticals.³ In view of the importance of biaryls, it is surprising that relatively few methods are available for their atroposelective synthesis in an operationally simple and scalable fashion.⁴ Current strategies⁵ include classical resolution of racemic biaryls, desymmetrization of preformed prochiral biaryls, dynamic kinetic resolution of rapidly racemizing preformed chiral biaryls,^{5c,i} transition-metal-catalyzed aryl–aryl coupling,^{4b,5d} de novo construction of an aromatic ring,^{5b,j} and central-to-axial chirality exchange^{5f,h,k} (Figure 1B).

As part of an ongoing program in the Kürti group to develop new and practical transition-metal-free direct arylation methods for the preparation of highly functionalized symmetrical and unsymmetrical biaryls,^{6a,5h,6b} we recently successfully exploited quinone and iminoquinone monoacetals as arylating agents to access both BINOL- and NOBIN-type functionalized biaryls that are atropoisomeric but non-*C*₂-symmetric from phenols and naphthols under organocatalytic conditions (**1** + **2** → **5**; Figure 2A).^{6b} We also briefly explored the possibility of using chiral BINOL-derived phosphoric acids as catalysts to obtain the biaryl products in an enantiomerically enriched form. Unfortunately, although moderate to good isolated yields were achieved, the level of enantioinduction was very poor (3–10% enantiomeric excess, *ee*), which we partially attributed to interference by the MeOH liberated during the formation of the mixed-acetal intermediate (**1** + **2** → **3**; Figure 2A);^{6b} addition of 3 Å molecular sieves (MS) did not improve the *ee*. We observed similar interference by proton donors (i.e., H₂O) during the catalytic synthesis of BINAM derivatives;^{5h} in that case the addition of 4 Å MS was advantageous.

On the basis of these findings,^{6b} we decided to redesign the quinone monoacetal coupling partner in a way that avoids the generation of a proton source (i.e., MeOH), thereby removing this potentially detrimental factor from the catalytic cycle.⁷ We selected readily available *N*-sulfonyl-protected iminoquinones as substrates, as these were expected to undergo acid-catalyzed in situ amination⁸ and subsequent [3,3]-rearrangement/rearomatization (Figure 2B). In contrast, a 1,4-addition mechanism was recently proposed by Tan and co-workers for a related reaction (Figure 2C).^{5k} We were pleased to observe that a 10 mol % loading of chiral phosphoric acid **7b** catalyzed the coupling of **6a** with **2a** under mild conditions and led to the formation of functionalized biaryl **9a** in excellent isolated yield with 49% *ee*. Encouraged by this initial result, we conducted a survey of structurally diverse BINOL-derived chiral phosphoric acid catalysts^{2d,9} and solvents to find the optimum conditions that maximize the enantiomeric excess of the product (Table 1; see the Supporting Information (SI) for details).

On the basis of the optimization studies described in Table 1, we selected DCE as the preferred solvent, chiral phosphoric acid **7c** (at 10 mol % loading) as the preferred catalyst, and either 25 or 50 °C as the optimum reaction temperature. At first we evaluated the coupling of iminoquinone **6a** with 14 structurally different hydroxyarenes, including 11 naphthols (Table 2, entries 1–11) and three monocyclic phenols (Table 2, entries 12–14).

For 2-naphthols, the biaryl products were formed in good to excellent yields, and the observed enantioselectivities ranged between 78 and 96% *ee*. No clear pattern showing how electron-withdrawing and electron-donating groups on the naphthalene ring influence the level of enantioinduction can be discerned.

The nearly perfect enantioselectivity (99% *ee*) obtained during the formation of terphenyl compound **9ea'** from 2,3-dihydroxynaphthalene (Table 2, entry 15) is remarkable and suggests that significant substrate stereocontrol occurs as the second biaryl linkage is established (see the discussion in the SI).

With one exception (Table 2, entry 14), monocyclic phenols afforded good levels of enantioinduction (entries 12 and 13). In a few cases (entries 1 and 5), using chlorobenzene as the solvent instead of DCE improved the enantioselectivity.

Next, we explored how structural changes (i.e., symmetry as well as size and nature of the substituents) in the iminoquinone (**6b–j**) influence the yield and enantioselectivity of the biaryl product (Table 3). Among the unsymmetrical iminoquinones **6b–e** that were coupled with 2,3-dihydroxynaphthalene (**2e**), the presence of a large substituent (i.e., *i*-Pr) at the ortho position of the *N*-Ts imine moiety led to a somewhat lower isolated yield and *ee* for **9ed** (entry 18) relative to isomeric **9eb** and **9ec** (entries 16 and 17) with a smaller Me substituent at the ortho position. Presumably, the larger *i*-Pr group slows amination formation and lowers the enantioselectivity of this step. The nature of the acyl/sulfonyl group on the N atom also appears to be important: the *ee* increases as more electron-withdrawing groups are used (i.e., Ts ≥ Ms > Ac > *p*-NO₂-benzoyl; compare **9aa** in Table 1 with entries 16, 23, and 24 in Table 2).

The most dramatic drop in the level of enantioinduction occurred when symmetrical (**6f**) and pseudosymmetrical (**6g**) iminoquinones were utilized as coupling partners (Table 3, entries 20 and 21). In fact, the poor *ee*'s observed for biaryls **9ef** and **9eg** provided us with a very valuable clue that helped us establish whether indeed amination formation as opposed to 1,4-addition is involved in the key stereochemistry-determining step.

On the basis of several experimental findings (Figure 3), it appears that in catalytic enantioselective processes where sequential chirality-transfer steps are involved, the highest level of enantioinduction will most likely take place in those cases where the catalyst does not “miss/skip” an opportunity to transfer chiral information. One way to “lose” or “skip” an opportunity for chirality transfer is when one or more symmetrical intermediates are formed along the pathway (see Figure 3A,C). Naturally, symmetrical (i.e., prochiral) intermediates can be desymmetrized using chiral catalysts, but the level of enantioinduction in these desymmetrizations must be very high, which is often difficult to achieve. In particular, organocatalytic asymmetric versions of the Claisen rearrangement are challenging, and there are only a few highly enantioselective examples in the literature.¹⁰

In light of the enantioinduction levels for biaryls **9ea** (96% *ee*) and **9eg** (21% *ee*), we can make a convincing mechanistic case for the involvement of sequential amination/ [3,3]-rearrangement. Figure 4 clearly shows that if a direct 1,4-addition were operational, the

influence of the highlighted extra methyl group could not account for the dramatic loss of enantioselectivity.

In conclusion, we have successfully developed a practical organocatalytic atroposelective synthesis of non- C_2 -symmetric BINOL derivatives starting from readily available hydroxyarenes and iminoquinones. The nearly two dozen axially chiral and structurally diverse functionalized biaryl products represent new chemical space and are expected to find broad utility in asymmetric catalysis, drug discovery, and materials science.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments


Financial support from the National Natural Science Foundation of China (81373303, 81473080, 81573299, and 21502230) is gratefully acknowledged. This project was also supported by the Jiangsu Province Natural Science Foundation (BK20150688), and the Program for Changjiang Scholars and Innovative Research Team in University (IRT1193). L.K. gratefully acknowledges the generous financial support from Rice University, NIH (R01 GM-114609-01), NSF (CAREER:-SusChEM CHE-1455335), the Robert A. Welch Foundation (Grant C-1764), ACS-PRF (Grant 51707-DNI1), Amgen (2014 Young Investigators' Award for L.K.), and Biotage (2015 Young Principal Investigator Award).

References


1. (a) Bringmann G, Mortimer AJP, Keller PA, Gresser MJ, Garner J, Breuning M. *Angew Chem, Int Ed.* 2005; 44:5384. (b) Wolf, C. *Dynamic Stereochemistry of Chiral Compounds: Principles and Applications*. Vol. Chapter 3. Royal Society of Chemistry; Cambridge, U.K.: 2007. (c) Bringmann G, Gulder T, Gulder TAM, Breuning M. *Chem Rev.* 2011; 111:563. [PubMed: 20939606] (d) Zask A, Murphy J, Ellestad GA. *Chirality.* 2013; 25:265. [PubMed: 23620262]
2. (a) Chen Y, Yekta S, Yudin AK. *Chem Rev.* 2003; 103:3155. [PubMed: 12914495] (b) Kocovsky P, Vyskocil S, Smrcina M. *Chem Rev.* 2003; 103:3213. [PubMed: 12914496] (c) Jacobsen, EN. Pfaltz, A., Yamamoto, H., editors. *Comprehensive Asymmetric Catalysis*. Springer; New York: 2004. (d) Akiyama T. *Chem Rev.* 2007; 107:5744. [PubMed: 17983247] (e) Blaser, H-U., Federsel, H-J., editors. *Asymmetric Catalysis on Industrial Scale: Challenges, Approaches, and Solutions*. 2. Wiley-VCH; Weinheim, Germany: 2010. (f) Corey, EJ., Kürti, L. *Enantioselective Chemical Synthesis: Methods, Logic and Practice*. Direct Book Publishing; Dallas, TX: 2010. (g) Ojima, I., editor. *Catalytic Asymmetric Synthesis*. 3. Wiley; Hoboken, NJ: 2010. (h) Busacca CA, Fandrick DR, Song JJ, Senanayake CH. *Adv Synth Catal.* 2011; 353:1825. (i) Magano J, Dunetz JR. *Chem Rev.* 2011; 111:2177. [PubMed: 21391570] (j) Zhou, Q-L., editor. *Privileged Chiral Ligands and Catalysts*. Wiley-VCH; Weinheim, Germany: 2011.
3. (a) Clayden J, Moran WJ, Edwards PJ, LaPlante SR. *Angew Chem, Int Ed.* 2009; 48:6398. (b) LaPlante SR, Edwards PJ, Fader LD, Jakalian A, Hucke O. *ChemMedChem.* 2011; 6:505. [PubMed: 21360821] (c) LaPlante SR, Fader LD, Fandrick KR, Fandrick DR, Hucke O, Kemper R, Miller SPF, Edwards PJ. *J Med Chem.* 2011; 54:7005. [PubMed: 21848318]
4. (a) Wallace TW. *Org Biomol Chem.* 2006; 4:3197. [PubMed: 17036104] (b) Kozlowski MC, Morgan BJ, Linton EC. *Chem Soc Rev.* 2009; 38:3193. [PubMed: 19847351] (c) Bencivenni G. *Synlett.* 2015; 26:1915. (d) Ma G, Sibi MP. *Chem -Eur J.* 2015; 21:11644. [PubMed: 26237330] (e) Wencel-Delord J, Panossian A, Leroux FR, Colobert F. *Chem Soc Rev.* 2015; 44:3418. [PubMed: 25904287] (f) Loxq P, Manoury E, Poli R, Deydier E, Labande A. *Coord Chem Rev.* 2016; 308:131.
5. (a) Bringmann G, Breuning M, Pfeifer RM, Schenk WA, Kamikawa K, Uemura M. *J Organomet Chem.* 2002; 661:31. (b) Tanaka K. *Chem - Asian J.* 2009; 4:508. [PubMed: 19101940] (c) Gustafson JL, Lim D, Miller SJ. *Science.* 2010; 328:1251. [PubMed: 20522769] (d) Shen X, Jones GO, Watson DA, Bhayana B, Buchwald SL. *J Am Chem Soc.* 2010; 132:11278. [PubMed:

- 20698695] (e) Cozzi PG, Emer E, Gualandi A. *Angew Chem, Int Ed.* 2011; 50:3847. (f) Guo F, Konkol LC, Thomson RJ. *J Am Chem Soc.* 2011; 133:18. [PubMed: 21141997] (g) De CK, Pesciaoli F, List B. *Angew Chem, Int Ed.* 2013; 52:9293. (h) Li GQ, Gao H, Keene C, Devonas M, Ess DH, Kürti L. *J Am Chem Soc.* 2013; 135:7414. [PubMed: 23659490] (i) Mori K, Ichikawa Y, Kobayashi M, Shibata Y, Yamanaka M, Akiyama T. *J Am Chem Soc.* 2013; 135:3964. [PubMed: 23413828] (j) Link A, Sparr C. *Angew Chem, Int Ed.* 2014; 53:5458. (k) Chen YH, Cheng DJ, Zhang J, Wang Y, Liu XY, Tan B. *J Am Chem Soc.* 2015; 137:15062. [PubMed: 26560999]
6. (a) Gao H, Ess DH, Yousufuddin M, Kürti L. *J Am Chem Soc.* 2013; 135:7086. [PubMed: 23470200] (b) Gao H, Xu QL, Keene C, Yousufuddin M, Ess DH, Kürti L. *Angew Chem, Int Ed.* 2016; 55:566.
7. Intriguingly, when the coupling between **2a** and **6a** to form biaryl **9a** was conducted in the presence of catalyst **7c** (10 mol %) and 1 equiv of MeOH (in DCE as the solvent), no detrimental impact on either the isolated yield (97%) or the enantiomeric excess (86% *ee*) was observed. However, when 20 equiv of MeOH was added, the reaction slowed dramatically and the isolated yield and *ee* dropped to 35% and 62%, respectively (at 50% conversion).
8. Li G, Fronczek FR, Antilla JC. *J Am Chem Soc.* 2008; 130:12216. [PubMed: 18722443]
9. (a) Kampen D, Reisinger CM, List B. *Top Curr Chem.* 2010; 291:395. [PubMed: 21494945] (b) Terada M. *Synthesis.* 2010; 2010:1929. (c) Parmar D, Sugiono E, Raja S, Rueping M. *Chem Rev.* 2014; 114:9047. [PubMed: 25203602]
10. (a) Uyeda C, Roetheli AR, Jacobsen EN. *Angew Chem, Int Ed.* 2010; 49:9753. (b) Rodrigues TCAF, Silva WA, Machado AHL. *Curr Org Synth.* 2015; 12:795.

A. Importance of Axially Chiral Biaryls




B. Current Atroposelective Methods



C. **THIS WORK:** Organocatalytic Atroposelective Direct Arylation




Figure 1. Organocatalytic atroposelective direct arylation of hydroxyarenes to afford non- C_2 -symmetric BINOLs.


A. Organocatalytic Synthesis of BINOL/NOBIN-Type Biaryls (Kürti):**B. New Design to Utilize *N*-Sulfonyl Iminoquinones (Xu, Sun & Kürti):****C. Atroposelective Synthesis of Axially Chiral Biaryldiols (Tan):****Figure 2.**

Development of our catalytic atroposelective direct arylation approach to non-*C*₂-symmetric BINOL derivatives (A,^{6b} B) and a recent report by Tan and co-workers (C).^{5k}

A. Symmetrical Quinone Monoacetal Leads to Symmetrical Mixed Acetal (Ref. 6b):



B. Unsymmetrical Iminoquinones Lead to Unsymmetrical (i.e., Chiral) Aminals:



C. Symmetrical & (Pseudo)Symmetrical Iminoquinones Lead to Symmetrical Aminals:




Figure 3.

Symmetries of intermediates in chirality transfer processes have a dramatic impact on the final products' ee.





Figure 4.

Case is made for the amination/[3,3]-rearrangement sequence as opposed to a direct 1,4-addition.

Table 1Catalyst Screen for the Atroposelective Synthesis of **9a** from **6a** and **2a**

Entry ^a	Solvent	Time (h)	<i>er</i> ^b	<i>ee</i> (%)
1	CH ₂ Cl ₂	48	88.5:11.5	77
2	toluene	48	86:14	72
3	1,2-dichloroethane (DCE)	48	94:6	88
4	CHCl ₃	48	90.5:9.5	81
5	chlorobenzene	84	97:3	94
6	1,3-di-CF ₃ -benzene	60	93:7	86
7 ^c	1,2-dichloroethane (DCE)	24	94:6	88
8 ^c	chlorobenzene	48	96:4	92
9 ^d	1,2-dichloroethane (DCE)	8	91:9	82
10 ^{c,e}	1,2-dichloroethane(DCE)	100	88.5:11.5	77

^a Reaction conditions: **2a** (0.075 mmol), **6a** (0.05 mmol), cat. (10 mol %), solvent (1 mL). Reactions were stopped when all of the **6a** was consumed.

^b Enantiomeric ratios were determined by HPLC analysis.

^c Reacted at 50 °C.

^d Reacted at 80 °C.

^e Using 5 mol % **7c**.

Table 2

Exploration of the Substrate Scope by Coupling of **6a** with Structurally Diverse Hydroxyarenes

Structure of Non-C ₂ -Symmetrical BINOLs	
(Entry) ^[a] ; Compound #, Isolated Yield (%) ^[b] , ee ^[c] , T and Time	
 (1) 9aa 97%; 88% ee (50 °C, 24 h) 91%; 92% ee (50 °C, 72h)	 (2) 9ba 87%; 92% ee (50 °C, 48 h)
 (3) 9ca 88%; 78% ee (50 °C, 48 h)	 (4) 9da 84%; 81% ee (50 °C, 48 h)
 (5) 9ea ^[d] 80%; 96% ee (rt, 1 h) 85%; 97% ee (r.t., 1.5 h)	 (6) 9fa 89%; 85% ee (50 °C, 48 h)
 (7) 9ga 78%; 85% ee (50 °C, 8 h)	 (8) 9ha 87%; 89% ee (50 °C, 48 h)
 (9) 9ia 90%; 87% ee (50 °C, 8 h)	 (10) 9ja 62%; 85% ee (50 °C, 72 h)
 (11) 9ka 99%; 83% ee (50 °C, 12 h)	 (12) 9la 64%; 76% ee (50 °C, 8 h)
 (13) 9ma 49%; 75% ee (50 °C, 72 h)	 (14) 9na 97%; 39% ee (rt, 72 h) ^[e]
 (15) 9ea' 90%; 99% ee (50 °C, 2h) ^[f]	 X-ray structure of 9ea' M.p. = 251-253 °C

^aReaction conditions: **2** (0.225 mmol), **6a** (0.15 mmol), cat. **7c** (10 mol %), DCE or chlorobenzene (3 mL), rt or 50 °C, unless indicated otherwise.^bReactions were stopped when all of the **6a** was consumed.^cDetermined by HPLC analysis.^dCompound **9ea** was obtained in 92% yield with 94% ee when the reaction was performed on a 3 mmol scale in chlorobenzene.^eAt 50 °C over 2 h the reaction proceeded in 97% yield to afford **9na** with 21% ee.

f
2a:6a ratio = 2.5:1; the absolute configuration of **9ea'** is (*R,R*).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Expansion of the Substrate Scope by Coupling of Structurally Diverse Iminoquinones

Structure of Non-C₂-Symmetrical BINOLs (Entry) ^[a] , Compound # , Isolated Yield (%) ^[b] , ee ^[c] , T and Time	
 (16) 9eb 98%; 87% ee (rt, 1 h)	 (17) 9ec 68%; 91% ee (rt, 2 h)
 (18) 9ed 63%; 73% ee (rt, 48 h)	 (19) 9ee 56%; 78% ee (rt, 1 h)
 (20) 9ef 31%; 4% ee (rt, 24 h)	 (21) 9eg 68%; 21% ee (rt, 3 h)
 (22) 9lc 48%; 83% ee (50 °C, 15 h)	 (23) 9eh 98%; 75% ee (rt, 3.5 h)
 (24) 9ei 69%; 58% ee (rt, 24 h)	 (25) 9aj combined: 99%; (9aj/9aj)* = 1/2 82% ee for 9aj; 25% ee for 9aj*

^aReaction conditions: **2** (0.225 mmol), **3a** (0.15 mmol), cat. **1c** (10 mol %), DCE or chlorobenzene (3 mL), rt or 50 °C.^bReactions were stopped when all of the **6b-j** was consumed.^cDetermined by HPLC analysis.^dCompound **9aj*** was found to racemize easily: even at room temperature overnight, the initial 25% ee decreased to 12% ee.